Notable Announces Leadership Team Expansion

FOSTER CITY, CA – April 09, 2020 (GLOBE NEWSWIRE) — Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its board has appointed veteran life science executive Laurie Heilmann as Chief Executive Officer. She succeeds founder Matt De Silva who will remain a member of Notable’s […]

MedTech Notable Labs launches rolling blood cancer trial to test its AI system

FOSTER CITY, CA – January 22, 2020 — Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, is launching its first self-sponsored clinical trial, designed from the ground up to help validate its cancer patient matching platform over the long term.

The 50 best workplaces for innovators

It’s not about the perks. For Fast Company‘s inaugural Best Workplaces for Innovators list, we set out to find companies that empower all employees—not just top executives, scientists, or coders—to create new products, improve operations, and take risks. We searched for businesses where innovation isn’t just a buzzword but a part of the value system […]

Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators

SAN FRANCISCO, Aug. 05, 2019 (GLOBE NEWSWIRE) — Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the traditional time and cost, announced today that it has been named to Fast Company’s inaugural Best Workplaces for Innovators list, honoring businesses and organizations that […]

Cancer Drug Discovery Firm Notable Nabs $40M in Series B Funding Round

NEW YORK – Notable, a Bay Area firm using automated laboratory testing, artificial intelligence, and single-cell omics for cancer drug discovery, said yesterday that it has raised $40 million in a Series B financing round to accelerate the development of its services. The financing was co-led by B Capital Group and returning investor LifeForce Capital. […]

Personalized cancer treatment startup Notable Labs nabs $40M Series B

Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company’s technology and growth of its commercial use cases. Silicon Valley startup Notable Labs, which uses AI to predict effective cancer treatments for patients, has raised a $40 million Series B round […]

AI-focused Notable Labs score $40M in funding; Seattle Genetics/Astellas submit marketing application for enfortumab vedotin

The AI experts at Notable Labs have garnered another $40 million to scale their automated laboratory and analytics platform. Designed to match patients to clinical trials by predicting quickly who are most likely to respond to a cancer drug, the startup has pitched itself as an advocate for patients and facilitator to pharma companies. With […]

Notable raises $40 million to personalize cancer drug regimens

Update: Notable has raised $40 million, not the $50 million suggested by the original headline. Notable Labs, a Foster City, California-based provider of personalized drug combination testing for cancer patients, today revealed that it’s closed a $40 million series B round co-led by B Capital Group and LifeForce Capital, with participation from B Capital and […]

Notable Labs lands $40M to expand AI-based cancer treatment tech

Since it raised its $10 million debut round in 2017, Notable Labs has been busy building its artificial-intelligence-based technology that predicts which types of patients are most likely to respond to a drug. Now, the startup is adding $40 million (PDF) to its reserves as it scales up its capabilities and plans to take its […]

Notable Announces $40m Series B Round to Fuel Development of Its Drug Discovery Platform for Personalized Oncology

SAN FRANCISCO, CA – July 16, 2019 – Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the traditional time and cost, announced a $40M Series B round. The round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning […]